HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $7
Karyopharm Therapeutics, Inc. +8.81% Pre
Karyopharm Therapeutics, Inc. KPTI | 0.90 0.90 | +8.81% 0.00% Pre |
HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:
KPTI) with a Buy and lowers the price target from $8 to $7.